Agios Pharmaceuticals (AGIO) News Today → How Biden has already won 2024 (From Porter & Company) (Ad) Free AGIO Stock Alerts $34.34 -0.66 (-1.89%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15, 2024 | americanbankingnews.comAgios Pharmaceuticals (NASDAQ:AGIO) Upgraded to Hold at StockNews.comMay 14, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Inovio Pharmaceuticals (INO)May 14, 2024 | globenewswire.comAgios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid CongressMay 6, 2024 | finance.yahoo.comAgios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024May 6, 2024 | marketbeat.comFisher Asset Management LLC Sells 106,543 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Fisher Asset Management LLC trimmed its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 13.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 710,876 shares of the biopharmaceutical company's stockMay 5, 2024 | finance.yahoo.comEarnings Beat: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 4, 2024 | finance.yahoo.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPSAgios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.64) by $0.19. The business had revenue of $8.19 million during the quarter, compared to the consensus estimate of $8.37 million. Agios Pharmaceuticals had a negative net margin of 1,312.64% and a negative return on equity of 38.08%. Agios Pharmaceuticals's quarterly revenue was up 46.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.47) EPS.May 3, 2024 | marketbeat.comThe Goldman Sachs Group Increases Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $33.00The Goldman Sachs Group increased their price target on shares of Agios Pharmaceuticals from $29.00 to $33.00 and gave the stock a "neutral" rating in a research report on Friday.May 3, 2024 | finance.yahoo.comAgios Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 3, 2024 | globenewswire.comAgios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024May 3, 2024 | finance.yahoo.comQ1 2024 Agios Pharmaceuticals Inc Earnings CallMay 2, 2024 | seekingalpha.comAgios Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 2, 2024 | investorplace.comAGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024May 2, 2024 | chron.comAgios Pharmaceuticals: Q1 Earnings SnapshotMay 2, 2024 | finance.yahoo.comAgios Pharmaceuticals Reports Q1 2024 Earnings: Narrower Loss than Expected with Strong Revenue ...May 2, 2024 | globenewswire.comAgios Reports Business Highlights and First Quarter 2024 Financial ResultsApril 23, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Shares Up 8.5%Agios Pharmaceuticals (NASDAQ:AGIO) Trading Up 8.5%April 18, 2024 | globenewswire.comAgios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024April 12, 2024 | insidertrades.comJacqualyn A. Fouse Sells 7,791 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) StockApril 10, 2024 | finance.yahoo.comDirector Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO)April 9, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Trading Up 5.2%Agios Pharmaceuticals (NASDAQ:AGIO) Shares Up 5.2%April 9, 2024 | finance.yahoo.comAgios Publishes 2024 Environmental, Social and Governance (ESG) ReportApril 9, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Given Overweight Rating at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Tuesday.April 6, 2024 | marketbeat.comAssenagon Asset Management S.A. Increases Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Assenagon Asset Management S.A. lifted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 478.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,504 shares oApril 3, 2024 | marketbeat.comVanguard Group Inc. Trims Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Vanguard Group Inc. cut its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 0.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,467,587 shares of the biopharmaceutical company's stock afterApril 2, 2024 | finanznachrichten.deOncoinvent AS: Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory BoardMarch 17, 2024 | marketbeat.comWellington Management Group LLP Sells 666,565 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Wellington Management Group LLP lowered its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 11.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 5,199,063 shares of the biopharmaceutical company's stock after selling 666,565 shares durinMarch 16, 2024 | finance.yahoo.comAGIO Apr 2024 40.000 callMarch 16, 2024 | finance.yahoo.comAGIO Apr 2024 25.000 putMarch 8, 2024 | uk.finance.yahoo.comAsset Purchase Deals in Pharmaceuticals and Biotechnology 2016-2024: Trends, Deal Structure, Leading Deals by Value, Most Active Dealmakers, and MoreMarch 5, 2024 | globenewswire.comAgios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024February 28, 2024 | morningstar.comAgios Pharmaceuticals Inc AGIOFebruary 24, 2024 | msn.comSCIEX’s Jose Castro-Perez Reveals How They're Setting New Standards in Mass SpectrometryFebruary 24, 2024 | msn.comAgios Pharmaceuticals (AGIO) Price Target Increased by 7.00% to 43.66February 23, 2024 | finance.yahoo.comAgios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key BenchmarkFebruary 23, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Price Target Cut to $30.00 by Analysts at JPMorgan Chase & Co.JPMorgan Chase & Co. reduced their price target on shares of Agios Pharmaceuticals from $31.00 to $30.00 and set a "neutral" rating for the company in a research report on Friday.February 23, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Hits New 12-Month High at $31.33Agios Pharmaceuticals (NASDAQ:AGIO) Hits New 52-Week High at $31.33February 22, 2024 | finance.yahoo.comAgios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024February 22, 2024 | marketbeat.comFY2024 EPS Estimates for Agios Pharmaceuticals, Inc. Reduced by Cantor Fitzgerald (NASDAQ:AGIO)Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Stock analysts at Cantor Fitzgerald reduced their FY2024 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a report issued on Monday, February 19th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the biophaFebruary 22, 2024 | globenewswire.comAgios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024February 21, 2024 | marketbeat.comRafferty Asset Management LLC Sells 29,983 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Rafferty Asset Management LLC reduced its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 18.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 133,624 shares of the biophFebruary 20, 2024 | finance.yahoo.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2023 Earnings Call TranscriptFebruary 18, 2024 | finance.yahoo.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Reported And Analysts Have Been Cutting Their EstimatesFebruary 17, 2024 | finance.yahoo.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Slashed This Year's EstimatesFebruary 16, 2024 | finance.yahoo.comAgios (AGIO) Q4 Earnings & Revenues Fall Short of EstimatesFebruary 16, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPSAgios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.64) by ($0.08). The firm had revenue of $7.10 million during the quarter, compared to analyst estimates of $7.80 million. Agios Pharmaceuticals had a negative return on equity of 22.03% and a negative net margin of 913.95%. The firm's revenue for the quarter was up 65.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.67 EPS.February 16, 2024 | marketbeat.comRoyal Bank of Canada Lowers Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $42.00Royal Bank of Canada cut their target price on shares of Agios Pharmaceuticals from $43.00 to $42.00 and set an "outperform" rating on the stock in a research note on Friday.February 16, 2024 | markets.businessinsider.comBuy Rating for Agios Pharma Amid Expanding Drug Pipeline and Strong Commercial ProspectsFebruary 16, 2024 | markets.businessinsider.comBuy Rating Justified by Agios Pharma’s Promising Trials and Future Prospects Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking $16T Elon Musk Crypto Leak (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. AGIO Media Mentions By Week AGIO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGIO News Sentiment▼0.000.42▲Average Medical News Sentiment AGIO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGIO Articles This Week▼33▲AGIO Articles Average Week Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Structure Therapeutics News Evotec News Galapagos News Catalyst Pharmaceuticals News Harmony Biosciences News NewAmsterdam Pharma News Syndax Pharmaceuticals News Edgewise Therapeutics News Amneal Pharmaceuticals News Schrödinger News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AGIO) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubNext President (Not Trump. Not Biden.)The Freeport SocietyCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
